Evidence map›Paper›PMID 36498709›Full record

ArticleJournal of clinical medicine2022

BDNF and proBDNF Serum Protein Levels in Obstructive Sleep Apnea Patients and Their Involvement in Insomnia and Depression Symptoms.

Agata Gabryelska, Szymon Turkiewicz, Marta Ditmer, Filip Franciszek Karuga, Dominik Strzelecki, Piotr Białasiewicz, Marcin Sochal

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Effects and safety ofFrontiers in pharmacology · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Agata GabryelskaDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 90-419 Lodz, Poland.ORCID 0000-0002-4430-6488
Szymon TurkiewiczDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 90-419 Lodz, Poland.ORCID 0000-0001-6399-8742
Marta DitmerDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 90-419 Lodz, Poland.
Filip Franciszek KarugaDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 90-419 Lodz, Poland.ORCID 0000-0002-6551-6804
Dominik StrzeleckiDepartment of Affective and Psychotic Disorders, Medical University of Lodz, 90-419 Lodz, Poland.ORCID 0000-0002-8559-1078
Piotr BiałasiewiczDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 90-419 Lodz, Poland.
Marcin SochalDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 90-419 Lodz, Poland.ORCID 0000-0003-2122-0304
Medical University of Lodz · PL

Funding

Ministry of Education and Science (Poland) SKN/SP/496681/2021
6 · The paper itself

Abstract

Introduction: Obstructive sleep apnea (OSA) is a disorder that, apart from somatic sequelae, increases the risk of developing psychiatric conditions. Brain-derived neurotrophic factor (BDNF) signaling pathway is involved in the pathophysiology of depression and insomnia. Therefore, the study aimed to investigate differences in concentrations of BDNF and proBDNF in patients with OSA and healthy individuals, to evaluate diurnal changes of these proteins, and to assess the correlations with psychiatric symptoms. Methods: Sixty individuals following polysomnography (PSG) were divided into two groups based on the apnea-hypopnea index (AHI): OSA patients (AHI ≥ 30; n = 30) and control group (AHI < 5; n = 30). Participants filled out questionnaires: Beck Depression Inventory (BDI), Athens Insomnia Scale (AIS), and Pittsburgh Sleep Quality Index (PSQI). Peripheral blood was collected before and after PSG. Protein concentrations were measured using ELISA. OSA group was divided into subgroups: AIS (−)/AIS (+) (AIS > 5), PSQI (−)/PSQI (+) (PSQI > 5), and BDI (−)/BDI (+) (BDI > 19). Results: No differences in BDNF and proBDNF protein levels were observed between OSA and the control groups. However, BDNF and proBDNF evening protein concentrations were higher in the AIS (+) and PSQI (+) groups (p < 0.001 for all). The BDI (+) group was characterized by lower morning levels of both proteins (p = 0.047 and p = 0.003, respectively). Conclusions: BDNF signaling pathway might be involved in the pathophysiology of depression and insomnia in patients with OSA. BDNF and proBDNF protein levels might be useful in defining OSA phenotypes.

Indexed as

BDNFdepressioninsomniaintermittent hypoxianeurotrophinsOSApolysomnographysleepiness

Identifiers

PMID36498709
PMCPMC9738137
OpenAlexW4311050897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.